dc.contributor.author |
Reva, Oleg N.
|
|
dc.contributor.author |
Rademan, Sunelle
|
|
dc.contributor.author |
Visagie, M.H. (Michelle Helen)
|
|
dc.contributor.author |
Lebelo, M.T. (Maphuti)
|
|
dc.contributor.author |
Gwangwa, Mokgadi Violet
|
|
dc.contributor.author |
Klochko, Vitalii V.
|
|
dc.contributor.author |
Joubert, Anna Margaretha
|
|
dc.contributor.author |
Lall, Namrita
|
|
dc.date.accessioned |
2019-06-19T13:54:51Z |
|
dc.date.available |
2019-06-19T13:54:51Z |
|
dc.date.issued |
2019 |
|
dc.description.abstract |
AIM : To determine the computer-predicted anticancer activity of mupirocin and to compare its activities with those determined for another polyene antibiotic, batumin. MATERIALS AND METHODS : Molecular docking, cytotoxicity assays, cell microscopy and cell cycle progression were studied in cancer and nontumorigenic cell lines. RESULTS AND CONCLUSION : Cytotoxicity of mupirocin against several cancerous cell lines was detected with the highest one (IC50 = 5.4 μg/ml) against melanoma cell line. The profile of cytotoxicity of mupirocin was similar to that reported for batumin. Nevertheless, the morphology of cells treated with these antibiotics and alterations in cell cycle progression suggested possible dissimilarity in their mechanisms of action. Selective cytotoxicity of mupirocin against melanoma cells potentiates further studies to discover nontoxic drugs for melanoma prevention. |
en_ZA |
dc.description.department |
Biochemistry |
en_ZA |
dc.description.department |
Genetics |
en_ZA |
dc.description.department |
Microbiology and Plant Pathology |
en_ZA |
dc.description.department |
Physiology |
en_ZA |
dc.description.department |
Plant Production and Soil Science |
en_ZA |
dc.description.librarian |
hj2019 |
en_ZA |
dc.description.sponsorship |
AM Joubert acquired grants from the National Research Foundation (NRF; 105992, 90523 and 85818), Cancer Association of South Africa (A0V741 and A0W228), the Struwig Germeshuysen Trust (A0N074), the School of Medicine Research Committee of the University of Pretoria (AOH561) and Medical Research Council (A0W110). MH Visagie was funded from the NRF (99706), the School of Medicine Research Committee of the University of Pretoria (AOH561) and Struwig Germeshysen Trust. N Lall was funded from NRF/IKS160514165042 Grant No: 105169. ON Reva was funded from NRF grant 105996. |
en_ZA |
dc.description.uri |
https://www.future-science.com/journal/fmc |
en_ZA |
dc.identifier.citation |
Reva, O.N., Rademan, S., Visagie, M.H. et al. 2019, 'Comparison of structures and cytotoxicity of mupirocin and batumin against melanoma and several other cancer cell lines', Future Medicinal Chemistry, vol. 11, no. 7, pp. 677-691. |
en_ZA |
dc.identifier.issn |
1756-8919 (print) |
|
dc.identifier.issn |
1756-8927 (online) |
|
dc.identifier.other |
10.4155/fmc-2018-0333 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/70250 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Future Science |
en_ZA |
dc.rights |
© 2019 Future Science Group |
en_ZA |
dc.subject |
Computer-predicted anticancer activity |
en_ZA |
dc.subject |
Mupirocin |
en_ZA |
dc.subject |
Polyene antibiotic |
en_ZA |
dc.subject |
Batumin |
en_ZA |
dc.subject |
Cancer cell lines |
en_ZA |
dc.subject |
Nontumorigenic cell lines |
en_ZA |
dc.subject |
Molecular docking |
en_ZA |
dc.subject |
Cell cycle progression |
en_ZA |
dc.subject |
Cytotoxicity assays |
en_ZA |
dc.subject |
Cell microscopy |
en_ZA |
dc.subject |
Melanoma |
en_ZA |
dc.subject |
Drug design |
en_ZA |
dc.subject |
Prophylaxis |
en_ZA |
dc.title |
Comparison of structures and cytotoxicity of mupirocin and batumin against melanoma and several other cancer cell lines |
en_ZA |
dc.type |
Preprint Article |
en_ZA |